258 related articles for article (PubMed ID: 1944436)
41. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma.
Johnson PW; Price CG; Smith T; Cotter FE; Meerabux J; Rohatiner AZ; Young BD; Lister TA
J Clin Oncol; 1994 Apr; 12(4):798-805. PubMed ID: 8151322
[TBL] [Abstract][Full Text] [Related]
42. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
[TBL] [Abstract][Full Text] [Related]
43. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow.
Gribben JG; Neuberg D; Barber M; Moore J; Pesek KW; Freedman AS; Nadler LM
Blood; 1994 Jun; 83(12):3800-7. PubMed ID: 8204898
[TBL] [Abstract][Full Text] [Related]
44. B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma.
Jacobsen E; Freedman A
Lancet Oncol; 2004 Dec; 5(12):711-7. PubMed ID: 15581541
[TBL] [Abstract][Full Text] [Related]
45. Purging with 4-hydroperoxycyclophosphamide.
Jones RJ
J Hematother; 1992; 1(4):343-8. PubMed ID: 1345676
[TBL] [Abstract][Full Text] [Related]
46. Detection of tumor contamination of peripheral stem cells in patients with lymphoma using cell culture and polymerase chain reaction technology.
Chan WC; Wu GQ; Greiner TC; Vose JM; Sharp JG
J Hematother; 1994; 3(3):175-84. PubMed ID: 7827867
[TBL] [Abstract][Full Text] [Related]
47. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Widmer L; Pichert G; Jost LM; Stahel RA
Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
[TBL] [Abstract][Full Text] [Related]
48. Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods.
Lambrechts AC; de Ruiter PE; Dorssers LC; van 't Veer MB
Leukemia; 1992 Jan; 6(1):29-34. PubMed ID: 1736011
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow purging for autologous bone marrow transplantation.
Gribben JG; Nadler LM
Leuk Lymphoma; 1993; 11 Suppl 2():141-8. PubMed ID: 8124225
[TBL] [Abstract][Full Text] [Related]
50. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging.
Negrin RS; Kiem HP; Schmidt-Wolf IG; Blume KG; Cleary ML
Blood; 1991 Feb; 77(3):654-60. PubMed ID: 1991175
[TBL] [Abstract][Full Text] [Related]
51. The use of photodynamic therapy in bone marrow purging.
Mulroney CM; Glück S; Ho AD
Semin Oncol; 1994 Dec; 21(6 Suppl 15):24-7. PubMed ID: 7992104
[TBL] [Abstract][Full Text] [Related]
52. Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging.
Negrin RS
J Hematother; 1992; 1(4):361-8. PubMed ID: 1345678
[TBL] [Abstract][Full Text] [Related]
53. Immunologic methods of purging in autologous stem cell transplantation.
Berkahn L
J Hematother Stem Cell Res; 2000 Apr; 9(2):147-59. PubMed ID: 10813528
[TBL] [Abstract][Full Text] [Related]
54. Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies.
Uckun FM; Myers DE
J Hematother; 1993; 2(2):155-63. PubMed ID: 7921971
[TBL] [Abstract][Full Text] [Related]
55. PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukaemia.
Vervoordeldonk SF; Merle PA; Behrendt H; Steenbergen EJ; van den Berg H; van Wering ER; von dem Borne AE; van der Schoot CE; van Leeuwen EF; Slaper-Cortenbach IC
Br J Haematol; 1997 Feb; 96(2):395-402. PubMed ID: 9029032
[TBL] [Abstract][Full Text] [Related]
56. Immunologic purging of marrow assessed by polymerase chain reaction.
Murgo AJ; Weinberger BB; Johnson JR
N Engl J Med; 1992 Apr; 326(17):1163-4. PubMed ID: 1345414
[No Abstract] [Full Text] [Related]
57. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).
Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG
Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059
[TBL] [Abstract][Full Text] [Related]
58. Ex vivo purging of stem cell autografts using cytotoxic cells.
Maki G
J Hematother Stem Cell Res; 2001 Aug; 10(4):545-51. PubMed ID: 11522237
[TBL] [Abstract][Full Text] [Related]
59. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
60. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation.
Saarinen UM; Wikström S; Mäkipernaa A; Lanning M; Perkkiö M; Hovi L; Rapola J; Sariola H
J Clin Oncol; 1996 Oct; 14(10):2791-802. PubMed ID: 8874341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
